Urinary Track Infection Prevention After Urogynecological Surgery
কীওয়ার্ডস
বিমূর্ত
বর্ণনা
Urinary tract infections (UTIs) are one of the most common bacterial infections in women. It is estimated that 1.6 billion dollars are spent on UTI treatment each year. Antibiotics have been the mainstay of treatment of UTIs, however frequent use has increased the prevalence of antibiotic resistant organisms. Therefore, focus has shifted to non-antibiotic therapy for UTI prophylaxis.
Methenamine Hippurate (MH) has been studied for decades due to its potential role in prevention of UTI. While not technically an antibiotic, MH works via its bacteriostatic action in the bladder. Benefits of MH are the lack of development of resistance, and the selective nature of this drug to the urinary system only. However, MH is best used in conjunction with an acidifying agent to increase its bioavailability (such as cranberry capsules or other acidic products). The usage of MH has been studied in various populations, has been seen to be effective in short-term catheterization. Usage of cranberry as prophylaxis for UTI is controversial; however, results have been favorable in the post-operative gynecological population.
Post-operative urinary retention (POUR) occurs frequently in patients who undergo incontinence and pelvic prolapse surgery. Although the definition of POUR can vary between clinicians, it is reported as 2.5-24% to as high as 43% after tension-free transvaginal mesh sling placement. This population is at also at high risk for UTI due to advanced age and menopausal status. Moreover, using a catheter longer than 2 days incurs a 2-fold increased risk of development of UTI with an estimated 5% increase in bacteriuria each day of catheterization.
In hopes to decrease the overuse of antibiotics and decrease the likelihood of antibiotic resistance, we propose that the use of MH and cranberry can reflect a potential benefit in this population of short-term indwelling Foley catheter use and help reduce the incidence of post-operative UTI after pelvic surgery.
The patients will then be randomized to either receive cranberry capsules and placebo OR cranberry capsules and Methenamine Hippurate.
তারিখ
| সর্বশেষ যাচাই করা হয়েছে: | 06/30/2020 |
| প্রথম জমা দেওয়া: | 01/22/2019 |
| আনুমানিক তালিকাভুক্তি জমা দেওয়া হয়েছে: | 01/22/2019 |
| প্রথম পোস্ট: | 01/27/2019 |
| সর্বশেষ আপডেট জমা দেওয়া হয়েছে: | 07/20/2020 |
| সর্বশেষ আপডেট পোস্ট: | 07/22/2020 |
| আসল অধ্যয়ন শুরুর তারিখ: | 06/16/2019 |
| আনুমানিক প্রাথমিক সমাপ্তির তারিখ: | 12/31/2020 |
| আনুমানিক অধ্যয়ন সমাপ্তির তারিখ: | 04/30/2021 |
অবস্থা বা রোগ
হস্তক্ষেপ / চিকিত্সা
Drug: Methenamine Hippurate with Cranberry
Drug: Placebo with Cranberry
পর্যায়
বাহু গ্রুপ
| বাহু | হস্তক্ষেপ / চিকিত্সা |
|---|---|
| Experimental: Methenamine Hippurate with Cranberry Subjects will be instructed to take Methenamine Hippurate 1 g tablet ( 1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days. | Drug: Methenamine Hippurate with Cranberry Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert). |
| Placebo Comparator: Placebo with Cranberry Subjects will be instructed to take Placebo tablet (1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
Cranberry capsules were incorporated into the standard practice of Cincinnati Urogynecology Associates, TriHealth Inc in mid-March 2016. | Drug: Placebo with Cranberry Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient. |
যোগ্যতার মানদণ্ড
| বয়স অধ্যয়নের জন্য যোগ্য | 18 Years প্রতি 18 Years |
| লিঙ্গ অধ্যয়নের জন্য যোগ্য | Female |
| স্বাস্থ্যকর স্বেচ্ছাসেবীদের গ্রহণ করে | হ্যাঁ |
| নির্ণায়ক | Inclusion Criteria: - Patients who undergo major pelvic organ prolapse surgery that are diagnosed with POUR via failed retrograde void trial and require an indwelling Foley catheter upon hospital discharge. Exclusion Criteria: - Unwillingness to participate in the study - Inability to understand English - Pregnant women - Patient personal history of nephrolithiasis, urogenital anomaly, neurogenic bladder, chronic renal insufficiency (GFR <60 ml/min/1.73 m² or serum creatinine level >1.03 for >3months), sarcoidosis, and severe hepatic insufficiency - Currently (prior 3 months) undergoing medical management for recurrent UTI or interstitial cystitis - Active urinary tract infection - Patient history of taking Warfarin (Coumadin) - Intraoperative bladder injury or cystotomy - Physical or mental impairment that would affect the subject's ability to take medications daily or fill out questionnaires - Reported allergy to any of the ingredients in the cranberry, MH, or placebo pill |
ফলাফল
প্রাথমিক ফলাফল ব্যবস্থা
1. Incidence of urinary track infection (UTI) [From surgery to one week post-op visit, approximately 1 week post surgery]
